Granzyme K inhibition for modulating inflammaging
This solution targets inflammaging by inhibiting Granzyme K, a protease linked to aging-related inflammation. It aims to restore immune and organ function in aged mice, offering a promising approach to mitigate age-related decline.
Overview
Granzyme K (Gzm K) has been identified as a key contributor to inflammaging, a chronic low-grade inflammation associated with aging. This innovative research focuses on inhibiting Gzm K to address the aging process at its core, particularly targeting the aged immune system. By inhibiting this protease, the solution aims to restore immune, tissue, and organ function, potentially reversing age-related decline in mice. This approach offers a novel pathway to treat aging as a disease, providing significant implications for enhancing the quality of life in the elderly.
Technical specifications
- Target molecule: Granzyme K, a pro-inflammatory protease associated with cellular senescence.
- Research model: Aging C57BL/6 mice, treated with Gzm K inhibitors to assess immune and organ function.
- Evaluation metrics: Ex vivo analysis of immune cell populations, tissue architecture, and organ response to stressors (e.g., salt loading, angiotensin II infusions).
- Outcome measures: Recovery of immune system function, reduction in tissue fibrosis, and improved organ resilience in treated mice.
Technology readiness level
This research is at Technology Readiness Level 4, indicating that the concept has been validated in laboratory settings with aging mice models. Further validation and development are needed to transition towards clinical applications.
About Monash University, Melbourne
Monash University is a comprehensive public research university and one of Australia’s largest, known for scale, interdisciplinarity, and an applied orientation. Its Melbourne-based technology precinct brings together university laboratories, pilot-scale and prototyping suites, and company R&D groups alongside government research organizations to enable co-development and rapid iteration. Integration with a major hospital network supports clinical trials and translation, while structured industry placements and doctoral partnerships create a robust talent pipeline for corporate R&D. Research is backed by competitive funding from the Australian Research Council, the National Health and Medical Research Council, and state and federal programs that incentivize industry collaboration. A dedicated technology transfer office manages IP, licensing, and startup formation, with pathways to incubation and investment within the precinct.
Inquire about this partnering listing
Industry applications
delivered to your inbox.